GlyTech is an Osaka venture founded in 2011. The business focus is on the synthesis of human-type glycosides applicable to the chemical synthesis of highly pure human glycoproteins, https://www.glytech.jp/jp/. Investment is from Nippon Shokubai, Fushimi Seiyaku, SBI Investment, Osaka University Venture Capital, and Italy’s MIAT SpA, a Milano-based chemical trader and investor.
Source: GlycoTech news release, May 28, 2018
Request a quote for deeper information from